Pediatrix Medical Group (NYSE:MD) Upgraded to “Buy” at StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Thursday.

Other analysts also recently issued research reports about the stock. Mizuho boosted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Truist Financial decreased their price target on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft raised their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. UBS Group upped their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Macquarie assumed coverage on Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price target for the company. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $16.25.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $12.46 on Thursday. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.07, a PEG ratio of 2.00 and a beta of 1.58. The business’s 50 day moving average is $14.35 and its two-hundred day moving average is $11.54. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter in the prior year, the company posted $0.29 earnings per share. Pediatrix Medical Group’s quarterly revenue was up .9% on a year-over-year basis. Research analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MD. Rubric Capital Management LP increased its position in Pediatrix Medical Group by 1.5% during the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after purchasing an additional 125,000 shares during the last quarter. State Street Corp increased its holdings in shares of Pediatrix Medical Group by 1.4% during the 3rd quarter. State Street Corp now owns 3,540,791 shares of the company’s stock worth $41,038,000 after buying an additional 50,597 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Pediatrix Medical Group by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after buying an additional 45,155 shares during the period. Dana Investment Advisors Inc. raised its position in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after buying an additional 455,785 shares during the period. Finally, Weiss Asset Management LP grew its position in Pediatrix Medical Group by 50.5% during the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after acquiring an additional 306,143 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.